Group 1 - The board of directors of Robotech Co., Ltd. held its 31st meeting on August 27, 2025, to review the company's 2025 semi-annual report, which was deemed to accurately reflect the company's operational status without any false records or misleading statements [1][2] - The board unanimously approved the management and use of raised funds in compliance with relevant regulations, confirming no violations or changes that could harm shareholder interests [2][3] - A three-year shareholder return plan (2025-2027) was established to enhance transparency and protect shareholder rights, which will be submitted for approval at the upcoming extraordinary general meeting [3][4] Group 2 - The board nominated candidates for the fourth board of directors, including both non-independent and independent directors, with all candidates receiving unanimous approval from the current board [5][6][8] - The company plans to appoint a new accounting firm, Zhitong CPA, following the expiration of the contract with the previous firm, Tianjian CPA, with both firms having no objections to the change [8][9] - Amendments to the company's governance structure and articles of association were approved to align with legal requirements and improve operational standards, pending further review at the extraordinary general meeting [10][11]

证券代码：300757 证券简称：罗博特科 公告编号：2025-073 罗博特科智能科技股份有限公司（以下简称"公司"）第三届监事会第二十七 次会议于 2025 年 8 月 27 日在苏州工业园区唯亭街道港浪路 3 号罗博特科 A 栋 四楼会议室以通讯表决的方式召开。本次会议通知已于 2025 年 8 月 15 日以电子 邮件形式通知全体监事。本次会议应出席监事 3 人，实际出席监事 3 人。本次会 议由公司监事会主席张学强先生召集并主持，本次会议的召集、召开及表决程序 符合《公司法》及《公司章程》的有关规定，会议决议合法有效。 二、监事会会议审议情况 本次会议以记名方式投票表决，审议通过了以下事项： 经审核，监事会认为：董事会编制和审议的公司《2025 年半年度报告》及 《2025 年半年度报告摘要》的程序符合相关法律法规，报告内容真实、准确、 完整地反映了公司 2025 年上半年度经营的实际情况，不存在虚假记载、误导性 陈述或重大遗漏。 具体内容详见公司同日刊登于巨潮资讯网（http://www.cninfo.com.cn）的 《2025 年半年度报告》和《2025 年半年度报告摘要》。 表决结果：3 票 ...

Core Viewpoint - The legal opinion letter from Beijing Zhonglun (Shenzhen) Law Firm confirms that Shenzhen Mingyang Circuit Technology Co., Ltd. is eligible to implement its 2025 Restricted Stock Incentive Plan, adhering to relevant laws and regulations [2][8][36]. Group 1: Company Overview - Shenzhen Mingyang Circuit Technology Co., Ltd. is a publicly listed company with a unified social credit code of 914403007298410748, established as a joint-stock limited company [10]. - The company is engaged in the development of information and communication products, including the production of multilayer circuit boards and flexible circuit boards [10][11]. Group 2: Incentive Plan Details - The 2025 Restricted Stock Incentive Plan aims to establish a long-term incentive mechanism to attract and retain talent, aligning the interests of shareholders, the company, and core team members [11][36]. - The plan proposes to grant a total of 4.82 million restricted stocks, accounting for 1.39% of the company's total share capital of 347.82 million shares [12][14]. Group 3: Stock Grant and Conditions - The grant of restricted stocks will be priced at 8.57 yuan per share, which is not lower than the par value and meets the required pricing conditions [22][36]. - The plan includes performance assessment criteria for the release of restrictions on stocks, with specific targets for revenue growth and net profit for the years 2025 to 2027 [24][26]. Group 4: Legal Compliance and Procedures - The company has fulfilled necessary legal procedures for the implementation of the incentive plan, including board approvals and public disclosures [27][30]. - The plan requires further approval from the shareholders' meeting before implementation, ensuring compliance with the relevant laws and regulations [37][38].

深圳明阳电路科技股份有限公司 一、限制性股票激励计划分配情况 深圳明阳电路科技股份有限公司 董 事 会 划草案公告时公司股本总额的 1.00%。公司全部有效期内的激励计划所涉及的标的股票总数累计不超 过本 激励计划草案公告时公司股本总额的 20.00%。 薪酬与考核委员会发表明确意见、律师发表专业意见并出具法律意见书后，公司在指定网站按要求及时 披 露激励对象相关信息。 东或实际控制人及其配偶、父母、子女。中层管理人员和核心骨干人员中陈德聪先生为中国香港籍。 | | | 获授的限制性 | | 占本激励计划 | | 占股本 | | --- | --- | --- | --- | --- | --- | --- | | 姓名 | 国籍 | 职务 | 股票数量 | | 授予限制性股 | 总额的 | | | | | （万股） | 票总数的比例 | | 比例 | | 胡诗益 | 中国 | 董事、副总经理 | | 35.00 | 7.26% | 0.10% | | 窦旭才 | 中国 | 董事、副总经理 | | 35.00 | 7.26% | 0.10% | | 赵春林 | 中国 | 董事 | 30.00 | 6.22% ...

证券代码：300739 证券简称：明阳电路 公告编号：2025-096 债券代码：123087 债券简称：明电转债 债券代码：123203 债券简称：明电转 02 深圳明阳电路科技股份有限公司 第四届董事会第七次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 深圳明阳电路科技股份有限公司（以下简称"公司"）第四届董事会第七次 会议（以下简称"会议"）于 2025 年 8 月 26 日以现场表决结合通讯表决的方式 召开。会议通知已于 2025 年 8 月 16 日以邮件、电话及专人送达等方式发出。会 议由公司董事长张佩珂先生主持，应到董事 7 人，实到董事 7 人（其中董事马旭 飞先生、LIN JIANWU（林健武）先生、李娟娟女士以通讯方式出席）。公司监事、 高级管理人员列席了会议。会议的召集和召开程序符合《中华人民共和国公司法》 及《公司章程》等有关规定，形成的决议合法有效。 二、董事会会议审议情况 （一）审议通过《关于<2025 年半年度报告>全文及摘要的议案》 公司编制的《2025 年半年度报告》全文及其摘要的相关内 ...

Core Viewpoint - The report confirms that the second vesting period of the 2023 restricted stock incentive plan for Beijing Tianzhihang Medical Technology Co., Ltd. has met the vesting conditions, allowing for the allocation of shares to eligible participants [6][10][16]. Summary by Sections Definitions - The report defines key terms related to the incentive plan, including "restricted stock," "incentive objects," and "vesting conditions," which are essential for understanding the plan's framework [1][2]. Approval Process - The 2023 restricted stock incentive plan has undergone necessary approval procedures, including resolutions from the board of directors and the supervisory board, confirming the plan's compliance with relevant regulations [4][6]. Vesting Conditions Achievement - The board of directors has reviewed and confirmed that the vesting conditions for the second vesting period have been met, allowing for the allocation of 3.86466 million shares to 148 eligible participants [6][10]. Performance Requirements - The performance requirements for the incentive plan include achieving a revenue growth rate of at least 40% for the first vesting period and 90% for the second vesting period, or obtaining medical device registration for at least two new orthopedic surgical robots [10][11]. Allocation Details - For the first grant, 95 participants are eligible to receive 3.135355 million shares, while for the reserved grant, 117 participants are eligible for 729305 shares, both at a grant price of 8.66 yuan per share [12][14][15]. Independent Financial Advisor's Opinion - The independent financial advisor concludes that the vesting conditions have been met and that the plan complies with relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [16].

Core Viewpoint - The legal opinion from Beijing Deheng Law Firm confirms that the second vesting period of the 2023 restricted stock incentive plan for Beijing Tianzhihang Medical Technology Co., Ltd. meets the vesting conditions and outlines the circumstances under which certain restricted stocks will be canceled [2][5][21]. Group 1: Approval and Authorization - The company has completed necessary procedures for the implementation of the 2023 restricted stock incentive plan, including approval from the board and supervisory committee [6][7]. - The independent directors have expressed that the implementation of the incentive plan is beneficial for the company's governance structure and does not harm the interests of shareholders, especially minority shareholders [7][8]. Group 2: Vesting Conditions - The second vesting period for the initial grant of restricted stocks began on May 12, 2023, and the pre-allocated grant's second vesting period will start on August 22, 2025 [10][11]. - The company has confirmed that the vesting conditions have been met, including the absence of negative audit opinions and compliance with legal regulations [11][14]. Group 3: Specifics of the Vesting - The initial grant date was May 12, 2023, with 95 individuals eligible for a total of 3.135355 million shares at a grant price of 8.66 yuan per share [20]. - The pre-allocated grant date is August 22, 2023, with 117 individuals eligible for a total of 0.729305 million shares at the same grant price [20]. Group 4: Cancellation of Restricted Stocks - A total of 172,095 restricted stocks will be canceled due to the departure of individuals who no longer meet the eligibility criteria [22]. - The cancellation aligns with the regulations set forth in the management measures and listing rules [21][22]. Group 5: Conclusion - The legal opinion concludes that both the vesting and cancellation of restricted stocks have received the necessary approvals and comply with relevant regulations [22][23].

证券代码：688277 证券简称：天智航 公告编号：2025-034 北京天智航医疗科技股份有限公司 关于作废 2023 年限制性股票激励计划部分已授予尚未归属 的限制性股票的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 北京天智航医疗科技股份有限公司（以下简称"公司"）于 2025 年 8 月 27 日召开的第六届董事会第二十二次会议、第五届监事会第十次会议，审议通过了 《关于作废 2023 年限制性股票激励计划部分已授予尚未归属的限制性股票的议 案》。现将有关事项说明如下： 一、本激励计划已履行的相关审批程序 了《关于公司<2023 年限制性股票激励计划（草案）>及其摘要的议案》《关于 公司<2023 年限制性股票激励计划实施考核管理办法>的议案》《关于提请股东 大会授权董事会办理公司 2023 年限制性股票激励计划有关事项的议案》等相关 议案。公司独立董事就本次激励计划相关议案发表了独立意见。 的信息在公司内部进行了公示。截至公示期满，公司监事会未收到任何人对本次 拟 激 励 对 象 提 出 的 异 议 。 ...

Core Points - The company announced that the second vesting period of the 2023 restricted stock incentive plan has met the vesting conditions, allowing for the vesting of 3.86466 million shares, which accounts for 0.85% of the company's total share capital [1][10][18] Group 1: Incentive Plan Overview - The total number of restricted stocks to be granted under the incentive plan is not to exceed 8.6875 million shares, with the initial grant accounting for 6.878 million shares (1.53% of total share capital) and the reserved grant accounting for 1.7195 million shares (0.38% of total share capital) [1][2] - The vesting schedule includes two periods: the first vesting period is 24 months after the initial grant, and the second vesting period is 36 months after the initial grant [2][10] Group 2: Performance Assessment Criteria - The performance assessment for the initial grant includes two conditions: a revenue growth rate of at least 90% in 2024 compared to 2022, or obtaining at least two new orthopedic surgical robots' medical device registration licenses during 2023-2024 [3][4] - For the reserved grant, the performance assessment criteria are similar but adjusted for the years 2024-2025, requiring a revenue growth rate of at least 140% in 2025 compared to 2022, or obtaining at least three new orthopedic surgical robots' medical device registration licenses during 2023-2025 [4][5] Group 3: Approval and Compliance - The incentive plan has undergone necessary approvals, including independent opinions from the board and the supervisory committee, confirming compliance with relevant regulations [6][15] - The supervisory committee verified the eligibility of 148 incentive recipients, with 95 from the initial grant and 117 from the reserved grant, confirming that the performance assessment results are compliant and truthful [18][20]

Core Viewpoint - The company announced the repurchase and cancellation of 8,000 restricted stocks from the 2025 incentive plan due to the departure of one incentive object, adjusting the repurchase price to 7.17 yuan per share [1][5][6]. Summary by Sections 1. Approval Process and Disclosure - The company held meetings to approve the repurchase and cancellation of restricted stocks, which included necessary reviews and disclosures [1][2][3]. 2. Reasons and Details for Repurchase - The repurchase is based on the incentive plan's provisions, as the departing employee no longer qualifies for the incentive [3][4]. - The adjusted repurchase price is calculated based on the previous price of 7.29 yuan minus a dividend of 0.12 yuan, resulting in 7.17 yuan per share [4][5]. 3. Financial Impact and Stock Structure - The total amount for the repurchase is 57,360 yuan plus interest, sourced from the company's own funds [5]. - Post-repurchase, the total share capital will decrease from 183,038,400 shares to 183,030,400 shares, with no change in the actual control of the company [5][6]. 4. Opinions from Committees - The Board's Compensation and Assessment Committee and the Supervisory Committee both agree that the repurchase and price adjustment comply with relevant regulations and will not harm shareholder interests [6][7]. 5. Legal Opinion - The legal opinion confirms that the repurchase and adjustments have received necessary authorizations and comply with applicable laws and regulations [7][8].